Compare ABVE & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ABVE | VSTM |
|---|---|---|
| Founded | 2019 | 2010 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 108.5M | 723.8M |
| IPO Year | N/A | 2012 |
| Metric | ABVE | VSTM |
|---|---|---|
| Price | $1.71 | $7.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $13.38 |
| AVG Volume (30 Days) | ★ 2.4M | 2.1M |
| Earning Date | 01-01-0001 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $213,446,206.00 | $13,379,000.00 |
| Revenue This Year | N/A | $183.10 |
| Revenue Next Year | N/A | $271.39 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 33.79 |
| 52 Week Low | $0.25 | $3.46 |
| 52 Week High | $6.56 | $11.25 |
| Indicator | ABVE | VSTM |
|---|---|---|
| Relative Strength Index (RSI) | 37.94 | 33.40 |
| Support Level | $1.55 | $9.13 |
| Resistance Level | $3.42 | $9.91 |
| Average True Range (ATR) | 0.30 | 0.62 |
| MACD | -0.08 | -0.32 |
| Stochastic Oscillator | 8.56 | 6.43 |
Above Food Ingredients Inc is a differentiated, regenerative ingredient company. Its products are made with real nutritious, flavorful ingredients and delivered with transparency. Its vision is to create a healthier world one seed, one field, and one bite at a time. With a robust chain of custody of plant proteins, enabled by scaled operations and infrastructure in primary agriculture and processing, and proprietary seed development capabilities that leverage the power of artificial intelligence driven genomics. The company delivers nutritious foods to businesses and consumers with traceability and sustainability. Above Food's consumer products and brands are available in grocers across Canada and the United States.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.